NEW YORK, July 22 /-/ -- NeoStem, Inc. (NYSE Amex: NBS) today announced that the Company was featured on CBS's Eye on New York City on Sunday morning July 19, 2009.
The segment focused on NeoStem which is the first company to provide healthy adults in the general public the ability to have their stem cells collected in a safe and non-invasive way. http://www.neostem.com/videolinks.php NeoStem(R) makes it Easy and Painless. Advances in technology allow increased numbers of stem cells residing in your bone marrow, to migrate into the peripheral blood, a process that occurs naturally in the body when there is stress or injury. The next step is apheresis, a painless and safe procedure (similar to giving platelets) which separates and collects, through a sterile, closed and disposable system, the stem cells from your peripheral blood. The remaining cells are immediately returned to you. The collection process usually lasts about 3-4 hours. The cells are then cryo-preserved.
The feature also discussed therapies which stem cells may be used to treat and referenced the statement of Dr. Max Gomez, CBS2's medical expert, that autologous adult stem cells "have become the cutting edge way to treat osteoarthritis of the knee, hip, and ankle and even back pain." He noted, "The promise appears to be so great that more than 1,000 clinical trials are testing stem cell therapies for various conditions and showing promising results for heart failure, diabetes, lupus and even macular degeneration." According to a recent report of a study Conducted by City of Hope National Medical Center, after undergoing stem cell transplantation patients developing secondary acute myeloid leukemia/myelodysplastic disease following adjuvant treatment for breast cancer can achieve durable remission.
"NeoStem is very focused on autologous adult stem cell therapies being developed for multiple diseases," says Dr. Robin Smith, Chief Executive Officer of NeoStem. The Company has entered into a number of licensing arrangements. including acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells. NeoStem's technologies to advance its position in the field of stem cell tissue regeneration has caught the interest of other publications. NeoStem was also featured in the Summer 2009 issue of Catalyst, a magazine of Connections, Developments and Insights in the Life Science Industry. This publication by Amper, Politziner and Mattia focused this issue on Pharmaceuticalization of stem cells and featured Celgene Cellular Therapeutics which is focused on stem cell therapies from human placenta and NeoStem.
About NeoStem, Inc.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. In 2009, the Company began to expand its operations into China in connection with the development of therapeutic adult stem cell technologies and is seeking to generate revenues through its regenerative medicine programs and technologies in China.
For more information, please visit: www.neostem.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results, including its success, if any, in developing adult stem cell therapies could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include without limitation whether the Company's technologies will lead to successful therapeutic treatments, the Company's ability to execute on its expansion plans in China and the "Risk Factors" described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and the Company's other periodic filings with the Securities and Exchange Commission. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Robin Smith, Chief Executive Officer